Research ArticleBioengineering

An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

See allHide authors and affiliations

Science Translational Medicine  22 Apr 2015:
Vol. 7, Issue 284, pp. 284ra57
DOI: 10.1126/scitranslmed.3010564

Drug-releasing implant tests cancer’s resolve

Predicting whether a patient will respond to a drug is not easy, often relying on empirical evidence. Toward personalized medicine, animal models of patient tumors have been developed as well as engineered cell-material combinations meant to replicate a tumor in vitro. But the true test of whether a tumor responds to a drug will be by evaluating the tumor itself, within its own microenvironment. To this end, Jonas et al. created miniature drug delivery vessels that can be implanted with a standard biopsy needle directly into the tumor. These vessels, less than 1 mm in diameter, contained up to 16 microwells that each released a bolus of drug into the surrounding tumor tissue. The device and its surrounding tissue were then removed with a larger coring needle to see if the cancer cells had responded to the drug—or combination of drugs. In mouse models of melanoma, breast, or prostate cancers, the local response to a common chemotherapeutic, doxorubicin, matched the tumor response to systemic therapy. Furthermore, in a mouse model of triple-negative breast cancer, tumor sensitivity to five different locally delivered cancer drugs was identical to tumor response after intravenous administration of drug; for instance, tumors were most responsive to paclitaxel and least responsive to lapatinib. Such tiny drug-releasing devices can be implanted at different locations within the tumor, overcoming issues with tumor heterogeneity, and allowing for reproducible evaluation of drug sensitivity directly within the patient.

View Full Text

Stay Connected to Science Translational Medicine